Peptic Ulcers:治療薬パイプラインレビュー(2014年上半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC4898IDB)
◆英語タイトル:Peptic Ulcers - Pipeline Review, H1 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC4898IDB
◆発行日:2014年4月28日
◆調査対象地域:グローバル
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Peptic Ulcers:治療薬パイプラインレビュー(2014年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Peptic Ulcers – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Peptic Ulcers – Pipeline Review, H1 2014’, provides an overview of the Peptic Ulcers’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peptic Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peptic Ulcers and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peptic Ulcers and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peptic Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peptic Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peptic Ulcers Overview 7
Therapeutics Development 8
Pipeline Products for Peptic Ulcers – Overview 8
Pipeline Products for Peptic Ulcers – Comparative Analysis 9
Peptic Ulcers – Therapeutics under Development by Companies 10
Peptic Ulcers – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Peptic Ulcers – Products under Development by Companies 15
Peptic Ulcers – Companies Involved in Therapeutics Development 16
Sequella, Inc. 16
AstraZeneca PLC 17
Takeda Pharmaceutical Company Limited 18
Indus Biotech Private Limited 19
aRigen Pharmaceuticals, Inc. 20
RaQualia Pharma Inc. 21
Rottapharm|Madaus 22
Peptic Ulcers – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 32
vonoprazan – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
esomeprazole magnesium ER – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(lansoprazole + aspirin) – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SQ-109 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
itriglumide – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ARH-1029 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RQ-00000774 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule For Peptic Ulcers – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
INDUS-905 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Peptic Ulcers – Recent Pipeline Updates 44
Peptic Ulcers – Dormant Projects 48
Peptic Ulcers – Discontinued Products 49
Peptic Ulcers – Product Development Milestones 50
Featured News & Press Releases 50
Sep 13, 2013: US appeals court issues temporary injunction against Hanmi’s 505(b)2 NDA Esomeprazole Strontium 50
Mar 27, 2013: Takeda Submits New Drug Application For Fixed-dose Combination Of Takepron And Low-Dose Aspirin In Japan 50
Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision 51
Feb 13, 2012: Horizon Pharma Modifies DUEXIS Marketing Authorization Application To Include Recently Approved Manufacturing Site 51
Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole 51
Jul 01, 2011: AstraZeneca’s NEXIUM Receives First Regulatory Approval In Japan For Treatment Of Acid-related Diseases 52
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 52
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 53
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 53
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products under Development for Peptic Ulcers, H1 2014 8
Number of Products under Development for Peptic Ulcers - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Peptic Ulcers - Pipeline by Sequella, Inc., H1 2014 16
Peptic Ulcers - Pipeline by AstraZeneca PLC, H1 2014 17
Peptic Ulcers - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 18
Peptic Ulcers - Pipeline by Indus Biotech Private Limited, H1 2014 19
Peptic Ulcers - Pipeline by aRigen Pharmaceuticals, Inc., H1 2014 20
Peptic Ulcers - Pipeline by RaQualia Pharma Inc., H1 2014 21
Peptic Ulcers - Pipeline by Rottapharm|Madaus, H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Assessment by Combination Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 31
Peptic Ulcers Therapeutics - Recent Pipeline Updates, H1 2014 44
Peptic Ulcers - Dormant Projects, H1 2014 48
Peptic Ulcers - Discontinued Products, H1 2014 49

List of Figures
Number of Products under Development for Peptic Ulcers, H1 2014 8
Number of Products under Development for Peptic Ulcers - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31

*** 掲載企業 ***

Sequella, Inc.
AstraZeneca PLC
Takeda Pharmaceutical Company Limited
Indus Biotech Private Limited
aRigen Pharmaceuticals, Inc.
RaQualia Pharma Inc.
Rottapharm|Madaus

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC4898IDB )"Peptic Ulcers:治療薬パイプラインレビュー(2014年上半期)" (英文:Peptic Ulcers - Pipeline Review, H1 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。